UCLM802
/ UTC Therap
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
June 09, 2025
Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
(clinicaltrials.gov)
- P=N/A | N=24 | Recruiting | Sponsor: Zhejiang University
New trial • Solid Tumor
May 08, 2023
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
(clinicaltrials.gov)
- P1 | N=87 | Recruiting | Sponsor: Zhejiang University
New P1 trial • Biliary Tract Cancer • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • IL10 • IL6 • MSLN
March 24, 2023
MSLN-targeted CAR-T Cells in Solid Tumors.
(clinicaltrials.gov)
- P1 | N=87 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
CAR T-Cell Therapy • Metastases • New P1 trial • Biliary Tract Cancer • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • IL10 • IL6 • MSLN
March 20, 2023
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
(clinicaltrials.gov)
- P1 | N=87 | Not yet recruiting | Sponsor: Peking University
CAR T-Cell Therapy • Metastases • New P1 trial • Biliary Tract Cancer • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • IL10 • IL6 • MSLN
March 01, 2023
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Shanghai Pudong Hospital | N=20 ➔ 0 | Recruiting ➔ Withdrawn
CAR T-Cell Therapy • Enrollment change • Metastases • Trial withdrawal • Oncology • Solid Tumor • MSLN
September 08, 2022
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: Shanghai Pudong Hospital
CAR T-Cell Therapy • New P1 trial • Oncology • Solid Tumor • MSLN
1 to 6
Of
6
Go to page
1